The medical community is excited with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s demonstrating significant potential in clinical trials for managing obesity. Unlike some available weight loss solutions, retatrutide appears to provide a greater substantial loss in body weight and benefit metabolic health, parti